A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydroch...

Mise à jour : Il y a 5 ans
Référence : EUCTR2005-000627-42

A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydrochloride

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To determine the safety of repeat doses of intravenous (IV) infusion of forodesine in patients with B-ALL, which under WHO Guidelines is now referred to as precursor B-lymphoblastic leukemia/lymphoma.


Critère d'inclusion

  • B-cell acute lymphoblastic leukemia (B-ALL), which under WHO Guidelines is now referred to as precursor B-lymphoblastic leukemia/lymphoma

Liens